Antibodies specific for neutrophic chemotactic factor
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsKouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
Life of this patent
Estimating the term…
Abstract
The present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.
Claims11
A hybridoma producing monoclonal antibodies having specific binding affinity for a neutrophil chemotactic factor polypeptide or fragment thereof, wherein said polypeptide has the following amino acid sequence represented by single letter code:
- NH.sub.2 -S-A-K-E-L-R-C-Q-C-I-K-T-Y-S-K-P-F-H-P-K-F-I-K-E-L-R -V-I-E-S-G-P-H-C-A-N-T-E-I-I-V-K-L-S-D-G-R-E-L-C-L-D-P-K -E-N-W-V-Q-R-V-V-E-K-F-L-K-R-A-E-N-S.
An anti-neutrophil chemotactic factor antibody having specific binding affinity for a neutrophil chemotactic factor polypeptide or fragment thereof, wherein said polypeptide has the following amino acid sequence represented by single letter code:
- NH.sub.2 -S-A-K-E-L-R-C-Q-C-I-K-T-Y-S-K-P-F-H-P-K-F-I-K-E-L-R -V-I-E-S-G-P-H-C-A-N-T-E-I-I-V-K-L-S-D-G-R-E-L-C-L-D-P-K -E-N-W-V-Q-R-V-V-E-K-F-L-K-R-A-E-N-S.
A kit for determining the level of neutrophil chemotactic factor polypeptide present in a sample, said kit comprising an antibody having a specific binding affinity for a neutrophil chemotactic factor polypeptide or fragment thereof, wherein said polypeptide has the following amino acid sequence represented by single letter code:
- NH.sub.2 -S-A-K-E-L-R-C-Q-C-I-K-T-Y-S-K-P-F-H-P-K-F-I-K-E-L-R -V-I-E-S-G-P-H-C-A-N-T-E-I-I-V-K-L-S-D-G-R-E-L-C-L-D-P-K -E-N-W-V-Q-R-V-V-E-K-F-L-K-R-A-E-N-S.
A pharmaceutical composition comprising an anti-neutrophil chemotactic factor antibody having specific binding affinity for a neutrophil chemotactic factor polypeptide or fragment thereof, wherein said polypeptide has the following amino acid sequence represented by single letter code:
- NH.sub.2 -S-A-K-E-L-R-C-Q-C-I-K-T-Y-S-K-P-F-H-P-K-F-I-K-E-L-R -V-I-E-S-G-P-H-C-A-N-T-E-I-I-V-K-L-S-D-G-R-E-L-C-L-D-P-K -E-N-W-V-Q-R-V-V-E-K-F-L-K-R-A-E-N-S. and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.